Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%)
< Home < Back

Dr. Reddy’s launches Levetiracetam in Sodium Chloride Injection in US Market

Date: 19-06-2018

Dr. Reddy’s Laboratories has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 ml (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation's Levetiracetam in Sodium Chloride Injection, approved by the US Food and Drug Administration (USFDA).

The Levetiracetam in Sodium Chloride Injection brand and generic had US sales of approximately $37 million MAT for the most recent twelve months ending in April 2018 according to IMS Health.

The company’s levetiracetam in Sodium Chloride Injection is available in strengths of 500 mg/100 mL (5 mg/mL), 1,000 mg/100 ml (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.